CMS announces drugs selected for third round of drug price negotiations
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations. Negotiations will occur this year and any resulting prices will become effective in 2028. CMS said the selected drugs accounted for nearly $27 billion, or nearly 6%, in total prescription drug spending under Parts D and B between November 2024 and October 2025. Additionally, CMS released a list of the top 50 negotiation-eligible drugs based on combined expenditures under Parts D and B.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. Theā¦
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.ā¦
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in itsā¦
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through aā¦
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Priceā¦
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiationā¦